Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

9 treatments under study, led by Purinostat Mesylate 40mgm2

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Active Not Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05563844Phase 2Active Not RecruitingPrimary

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

NCT05526313Phase 1CompletedPrimary

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Showing all 2 trials

Research Network

Common Treatments

  • Purinostat Mesylate 40mgm21
  • Pm 112 Mgm21
  • Purinostat Mesylate 15mgm21
  • Purinostat Mesylate 24mgm21
  • Purinostat Mesylate 84mgm21

Active Sponsors

  • Chengdu Zenitar Biomedical Technology Co., Ltd2

Top Investigators

Activity Timeline